In a reversal, the National Institute for Health and Clinical Excellence says Aricept, Razadyne and Exelon are worth the money when it comes to treating people with mild Alzheimer's disease. Four years ago the gatekeeper recommended against them.
Read More...
Read the complete post at http://www.npr.org/blogs/health/2010/10/07/130397362/british-health-service-gives-alzheimer-s-drugs-a-second-chance?ft=1&f=103537970
Posted
Oct 07 2010, 06:13 AM
by
NPR Blogs: Shots - Health News Blog